ESMO: Adding Abiraterone Improves Survival in De Novo Metastatic Prostate Cancer

THURSDAY, Oct. 29, 2026-- The addition of abiraterone to standard treatment improves survival for men with de novo metastatic castration-sensitive prostate cancer (mCSPC), according to a study presented at the annual meeting of the European...